Veranex Preclinical Services, France (Formerly known as IMMR)

Veranex Preclinical Services, France (Formerly known as IMMR) is a prominent player in the MedTech and Biotech industries, with a primary focus on conducting preclinical studies in large models. The company, headquartered in Paris, prides itself on its world-class expertise in product design, clinical development, and regulatory affairs, offering a comprehensive solution from concept to commercial success. With a specialization in complex cardiovascular procedures, the company also boasts broad experience and capabilities across various non-cardiovascular disease areas, including neurostimulation, orthopedics, and robotics. Founded in 2003, Veranex has established itself as a market leader with its state-of-the-art, FDA-inspected and AAALAC International-accredited facilities, ensuring the successful completion of sophisticated studies with novel medical technologies. The company's full-service approach not only saves costs and time but also adheres to the highest ethical standards, excelling in procedures from early feasibility studies to GLP studies for worldwide regulatory approvals. Veranex's success can be attributed to its expert team of professionals with over 30 years of shared experience, resulting in low procedural complications and high success rates. The company's track record of partnering with more than 80 clients from 15 countries in the last 2 years speaks volumes about its global impact. The state-of-the-art facility with 5 operating rooms, including 2 hybrid ORs, and advanced imaging capabilities further underlines its commitment to excellence. Overall, Veranex Preclinical Services, France, stands out as a reliable and innovative partner for companies seeking to navigate the complexities of preclinical studies and expedite their path to market entry.